Ticker brief
ASND ASCENDIS PHARMA A/S
Consumer, Non-cyclical · Pharmaceuticals
last close
$243.37
1 day
+0.2%
14 days
+6.2%
mkt cap
·
signals 14d
6
authors 14d
3
crowd 14d
-0.5σ
Sentiment — last 14 days
daily mean sentiment, 2026-10-07 → 2026-10-16 · now +0.35 (−1 bearish … +1 bullish)
Who spoke3
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 4 | +0.09 |
| @StockMKTNewz | C | -0.83 | 1 | +0.00 |
| @himshouse | C | -0.89 | 1 | +0.05 |
Recent signals6of 6 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @OzmosiHealth | +0.35 | TransCon CNP received a positive CHMP opinion for treating pediatric achondroplasia. | +8.0% | tweet ↗ |
| 2026-10-15 | @himshouse | +0.05 | REX Shares launched peptide ETF PEPT; Hims was excluded and named firms are top holdings. | +7.4% | tweet ↗ |
| 2026-10-14 | @StockMKTNewz | +0.00 | Rex Shares launched the PEPT ETF and disclosed its largest holdings. | +7.2% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 lonapegsomatropin results for 2026-10-11. | +6.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 navepegritide results for 2026-10-11. | +6.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 navepegritide results for 2026-10-10. | +6.5% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.